BIT Capital GmbH Has $10.19 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)

BIT Capital GmbH grew its position in Ascendis Pharma A/S (NASDAQ:ASND) by 8.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 73,990 shares of the biotechnology company’s stock after acquiring an additional 5,569 shares during the period. Ascendis Pharma A/S comprises about 0.8% of BIT Capital GmbH’s portfolio, making the stock its 21st largest holding. BIT Capital GmbH owned 0.12% of Ascendis Pharma A/S worth $10,186,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. grew its holdings in Ascendis Pharma A/S by 94.4% during the fourth quarter. JPMorgan Chase & Co. now owns 77,427 shares of the biotechnology company’s stock worth $10,659,000 after purchasing an additional 37,593 shares during the period. Artisan Partners Limited Partnership raised its stake in Ascendis Pharma A/S by 0.9% in the fourth quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company’s stock valued at $612,689,000 after buying an additional 39,309 shares during the period. LPL Financial LLC lifted its position in shares of Ascendis Pharma A/S by 60.1% in the fourth quarter. LPL Financial LLC now owns 4,199 shares of the biotechnology company’s stock valued at $578,000 after buying an additional 1,577 shares during the last quarter. American Century Companies Inc. boosted its stake in shares of Ascendis Pharma A/S by 17.5% during the 4th quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company’s stock worth $56,072,000 after acquiring an additional 60,548 shares during the period. Finally, Corient Private Wealth LLC acquired a new position in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $450,000.

Wall Street Analysts Forecast Growth

ASND has been the subject of several research reports. Cantor Fitzgerald raised their price target on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, February 25th. Evercore ISI raised their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 18th. Morgan Stanley set a $180.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday, February 18th. The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. upped their target price on Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, March 18th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and a consensus target price of $204.64.

Ascendis Pharma A/S Trading Down 1.7 %

Shares of ASND stock opened at $158.28 on Thursday. The stock has a 50 day simple moving average of $143.11 and a 200 day simple moving average of $136.60. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $169.37. The stock has a market cap of $9.61 billion, a P/E ratio of -22.29 and a beta of 0.62.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. Analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.